Is There a Generic for Trelegy Ellipta?
No, no generic version of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is available in the US as of now. The drug, approved in 2017 for COPD and asthma, remains protected by multiple patents held by GlaxoSmithKline (GSK) and Innoviva, with the longest-running ones expiring in 2032–2033.[1][2]
When Do Trelegy Patents Expire?
Key US patents cover the inhaler formulation and combination, listed in the FDA's Orange Book. The primary composition patent (US 8,161,961) expires March 28, 2033, while others on the device extend to October 2032. Pediatric exclusivity adds six months to some, pushing effective expiry to 2033.[2]
Are There Any FDA-Approved Generics or Alternatives?
No ANDAs for generic Trelegy have been approved. GSK reports no Paragraph IV challenges filed yet, though generic makers like Mylan and Teva have shown interest in inhaled combos. Until expiry or successful litigation, generics can't launch without a settlement or court ruling.[1][2]
What About Authorized Generics or Competitors?
GSK has no authorized generic. Breztri Aerosphere (budesonide/glycopyrrolate/formoterol, from AstraZeneca) is the closest competitor—a triple inhaled therapy approved in 2020 for COPD—but it's branded with patents to 2034. No direct generic swaps exist.[3]
Can Biosimilars Replace Trelegy?
Trelegy isn't a biologic, so generics (not biosimilars) apply under the ANDA pathway. Inhaler complexity often delays entries due to device patents and bioequivalence hurdles.[2]
Cost and Access Options While Waiting
Trelegy lists at $700–$800 for a 30-day supply without insurance. Patient assistance via GSK's program or copay cards cuts costs to $0–$25 for eligible users. Cheaper inhaled alternatives like Advair generics (fluticasone/salmeterol) exist for dual therapy but lack the triple action.[4]
[1]: FDA Orange Book
[2]: DrugPatentWatch.com - Trelegy Ellipta
[3]: FDA Approval Data - Breztri
[4]: GoodRx - Trelegy Pricing